Clinical trials for this groundbreaking development are set to begin next year.
A new approach to neurological disorders?
The molecule, iQ-007, has completed preclinical development for drug-resistant epilepsy. According to Kamiński, it functions as a first-in-class, small molecule positive allosteric modulator of the EAAT2 glutamate transporter. EAAT2, primarily expressed in the central nervous system, plays a key role in removing excess glutamate from synaptic spaces, thereby reducing the risk of neurotoxicity.
"This molecule represents a novel therapeutic approach," said Kamiński. "By modulating EAAT2, it helps manage excess glutamate levels, which is crucial in preventing excitotoxicity, a process linked to many neurological disorders."
Broader potential for treating multiple conditions
In addition to epilepsy, researchers believe iQ-007 could offer new therapeutic avenues for a range of neurological, neurodegenerative, and psychiatric conditions where glutamate regulation is key. These include Alzheimer's, Parkinson's, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, ischemic stroke, pain, schizophrenia, depression, anxiety, and even addiction.
Global collaboration, commercialization
The development of iQ-007 has been a collaborative effort, involving research groups from Poland and several international institutions, including the Medical University of Warsaw, the Institute of Pharmacology PAN, and prominent universities such as Harvard Medical School, the University of Oslo, and Drexel University College of Medicine.
In 2020, the molecule was commercialized through the Jagiellonian University's Technology Transfer Center, CITTRU. It was licensed to iQure Pharma, a U.S.-based biotech company, which has partnered with Jagiellonian researchers to complete the preclinical phase.
(jh)
Source: TVP Kraków